Stopping
cancer requires understanding the patient’s tumor expression
Stopping cancer requires
new targets
Stopping
cancer requires new therapies and new combinations
Stopping cancer
is our mission
Sirexatamab
(DKN-01)
– an anti-DKK1 antibody
A new targeted therapy in development for cancer patients with high DKK1
learn more
News releases
Aug 12, 2026
Join our team
Leap Therapeutics is focused on developing targeted and immuno-oncology therapeutics. Leap’s most advanced clinical candidate, sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. Sirexatamab is being developed in patients with colorectal, esophagogastric, and gynecologic cancers. Leap also has FL-501, a humanized monoclonal antibody targeting the growth and differentiation factor 15 (GDF-15) protein, in preclinical development.
